Advertisement

Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement

Published:October 19, 2021DOI:https://doi.org/10.1016/j.ygyno.2021.10.008

      Highlights

      • Available prospective evidence is mixed for whether SCR improves overall survival.
      • Reviewing similarities & differences of clinical trials is key to applying findings to practice.
      • GOG-0213, DESKTOP III, and SOC-1 enrolled highly selected cohorts of patients.
      • Patient selection is critical when considering SCR as part of treatment for recurrent disease.
      • The goal of SCR should be complete resection of all visible disease.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J. Clin. 2021; 71: 209-249
        • National Comprehensive Cancer Network
        Ovarian Cancer, Version 1.2020.
        (Updated 3/11/2020. Accessed 5/2020)
        • Griffiths C.T.
        Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
        Natl. Cancer Inst. Monogr. 1975; 42: 101-104
        • Hoskins W.J.
        • Bundy B.N.
        • Thigpen J.T.
        • Omura G.A.
        The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 1992; 47: 159-166
        • Wimberger P.
        • Lehmann N.
        • Kimmig R.
        • et al.
        Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian Cancer study group (AGO-OVAR).
        Gynecol. Oncol. 2007; 106: 69-74
        • Bristow R.E.
        • Tomacruz R.S.
        • Armstrong D.K.
        • Trimble E.L.
        • Montz F.J.
        Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
        J. Clin. Oncol. 2002; 20: 1248-1259
        • Winter 3rd, W.E.
        • Maxwell G.L.
        • Tian C.
        • et al.
        Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2007; 25: 3621-3627
        • Scarabelli C.
        • Gallo A.
        • Carbone A.
        Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
        Gynecol. Oncol. 2001; 83: 504-512
        • Chi D.S.
        • McCaughty K.
        • Diaz J.P.
        • et al.
        Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
        Cancer. 2006; 106: 1933-1939
        • Pfisterer J.
        • Harter P.
        • Canzler U.
        • et al.
        The role of surgery in recurrent ovarian cancer.
        Int. J. Gynecol. Cancer. 2005; 15: 195-198
        • Morris M.
        • Gershenson D.M.
        • Wharton J.T.
        • Copeland L.J.
        • Edwards C.L.
        • Stringer C.A.
        Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
        Gynecol. Oncol. 1989; 34: 334-338
        • Janicke F.
        • Holscher M.
        • Kuhn W.
        • et al.
        Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.
        Cancer. 1992; 70: 2129-2136
        • Segna R.A.
        • Dottino P.R.
        • Mandeli J.P.
        • Konsker K.
        • Cohen C.J.
        Secondary cytoreduction for ovarian cancer following cisplatin therapy.
        J. Clin. Oncol. 1993; 11: 434-439
        • Eisenkop S.M.
        • Friedman R.L.
        • Wang H.J.
        Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
        Cancer. 1995; 76: 1606-1614
        • Vaccarello L.
        • Rubin S.C.
        • Vlamis V.
        • et al.
        Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
        Gynecol. Oncol. 1995; 57: 61-65
        • Landoni F.
        • Pellegrino A.
        • Cormio G.
        • Milani R.
        • Maggioni A.
        • Mangioni C.
        Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy.
        Acta Obstet. Gynecol. Scand. 1998; 77: 233-237
        • Cormio G.
        • di Vagno G.
        • Cazzolla A.
        • et al.
        Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature.
        Eur. J. Obstet. Gynecol. Reprod. Biol. 1999; 86: 185-188
        • Eisenkop S.M.
        • Friedman R.L.
        • Spirtos N.M.
        The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.
        Cancer. 2000; 88: 144-153
        • Gadducci A.
        • Iacconi P.
        • Cosio S.
        • Fanucchi A.
        • Cristofani R.
        • Riccardo Genazzani A.
        Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
        Gynecol. Oncol. 2000; 79: 344-349
        • Zang R.Y.
        • Zhang Z.Y.
        • Li Z.T.
        • et al.
        Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
        J. Surg. Oncol. 2000; 75: 24-30
        • Chen L.M.
        • Karlan B.Y.
        Recurrent ovarian carcinoma: is there a place for surgery?.
        Semin. Surg. Oncol. 2000; 19: 62-68
        • Munkarah A.
        • Levenback C.
        • Wolf J.K.
        • et al.
        Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
        Gynecol. Oncol. 2001; 81: 237-241
        • Tay E.H.
        • Grant P.T.
        • Gebski V.
        • Hacker N.F.
        Secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
        Obstet. Gynecol. 2002; 99: 1008-1013
        • Merideth M.A.
        • Cliby W.A.
        • Keeney G.L.
        • Lesnick T.G.
        • Nagorney D.M.
        • Podratz K.C.
        Hepatic resection for metachronous metastases from ovarian carcinoma.
        Gynecol. Oncol. 2003; 89: 16-21
        • Zang R.Y.
        • Li Z.T.
        • Tang J.
        • et al.
        Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?.
        Cancer. 2004; 100: 1152-1161
        • Gronlund B.
        • Lundvall L.
        • Christensen I.J.
        • Knudsen J.B.
        • Hogdall C.
        Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.
        Eur. J. Surg. Oncol. 2005; 31: 67-73
        • Gungor M.
        • Ortac F.
        • Arvas M.
        • Kosebay D.
        • Sonmezer M.
        • Kose K.
        The role of secondary cytoreductive surgery for recurrent ovarian cancer.
        Gynecol. Oncol. 2005; 97: 74-79
        • Onda T.
        • Yoshikawa H.
        • Yasugi T.
        • Yamada M.
        • Matsumoto K.
        • Taketani Y.
        Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.
        Br. J. Cancer. 2005; 92: 1026-1032
        • Ayhan A.
        • Gultekin M.
        • Taskiran C.
        • et al.
        The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience.
        Am. J. Obstet. Gynecol. 2006; 194: 49-56
        • Matsumoto A.
        • Higuchi T.
        • Yura S.
        • et al.
        Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
        J. Obstet. Gynaecol. Res. 2006; 32: 580-587
        • Benedetti Panici P.
        • De Vivo A.
        • Bellati F.
        • et al.
        Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
        Ann. Surg. Oncol. 2007; 14: 1136-1142
        • Salani R.
        • Santillan A.
        • Zahurak M.L.
        • et al.
        Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
        Cancer. 2007; 109: 685-691
        • Tebes S.J.
        • Sayer R.A.
        • Palmer J.M.
        • Tebes C.C.
        • Martino M.A.
        • Hoffman M.S.
        Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
        Gynecol. Oncol. 2007; 106: 482-487
        • Coleman R.L.
        • Spirtos N.M.
        • Enserro D.
        • et al.
        Secondary surgical cytoreduction for recurrent ovarian cancer.
        N. Engl. J. Med. 2019; 381: 1929-1939
        • Shi T.
        • Zhu J.
        • Feng Y.
        • et al.
        Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2021; 22: 439-449
        • Bois A.D.
        • Sehouli J.
        • Vergote I.
        • et al.
        Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
        Journal of Clinical Oncology. 2020; 38: 6000
        • Covens A.L.
        A critique of surgical cytoreduction in advanced ovarian cancer.
        Gynecol. Oncol. 2000; 78: 269-274
        • van der Burg M.E.
        • van Lent M.
        • Buyse M.
        • et al.
        The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer cooperative Group of the European Organization for research and treatment of Cancer.
        N. Engl. J. Med. 1995; 332: 629-634
        • Rose P.G.
        • Nerenstone S.
        • Brady M.F.
        • et al.
        Secondary surgical cytoreduction for advanced ovarian carcinoma.
        N. Engl. J. Med. 2004; 351: 2489-2497
        • Berek J.S.
        • Hacker N.F.
        • Lagasse L.D.
        • Nieberg R.K.
        • Elashoff R.M.
        Survival of patients following secondary cytoreductive surgery in ovarian cancer.
        Obstet. Gynecol. 1983; 61: 189-193
        • Harter P.
        • du Bois A.
        • Hahmann M.
        • et al.
        Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
        Ann. Surg. Oncol. 2006; 13: 1702-1710
        • Bristow R.E.
        • Puri I.
        • Chi D.S.
        Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
        Gynecol. Oncol. 2009; 112: 265-274
        • van de Laar R.
        • Kruitwagen R.F.
        • Zusterzeel P.L.
        • Van Gorp T.
        • Massuger L.F.
        Correspondence: premature stop of the SOCceR trial, a multicenter randomized controlled trial on secondary cytoreductive surgery: Netherlands trial register number: NTR3337.
        Int. J. Gynecol. Cancer. 2017; 27: 2
        • Tian W.J.
        • Chi D.S.
        • Sehouli J.
        • et al.
        A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
        Ann. Surg. Oncol. 2012; 19: 597-604
        • Coleman R.L.
        • Brady M.F.
        • Herzog T.J.
        • et al.
        Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2017; 18: 779-791
        • Fleming N.D.
        • Nick A.M.
        • Coleman R.L.
        • et al.
        Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer.
        Obstet. Gynecol. 2018; 132: 545-554
        • Fagotti A.
        • Ferrandina G.
        • Fanfani F.
        • et al.
        Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.
        Am J Obstet Gynecol. 2008; 199 (642 e641–646)
        • Fagotti A.
        • Fanfani F.
        • Ludovisi M.
        • et al.
        Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study.
        Gynecol. Oncol. 2005; 96: 729-735